Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553710 | 0.86 | LMNA (0.51) | LMNASMN1; SMN2ALDH1A1THRBKMT2A | |
| SCHEMBL22286153 | 0.84 | MAPK1 (0.53) | LMNASMN1; SMN2ALDH1A1THRBKMT2A | |
| SCHEMBL20552143 | 0.83 | LMNA (0.51) | LMNASMN1; SMN2ALDH1A1THRBKMT2A | |
| SCHEMBL20551881 | 0.82 | MAPK1 (0.51) | LMNASMN1; SMN2ALDH1A1THRBKMT2A | |
| SCHEMBL20551725 | 0.81 | LMNA (0.45) | LMNASMN1; SMN2ALDH1A1THRBKMT2A | |
| SCHEMBL20551788 | 0.81 | HPGD (0.51) | LMNASMN1; SMN2ALDH1A1MAPK1TSHR | |
| SCHEMBL20551859 | 0.81 | LMNA (0.57) | LMNASMN1; SMN2ALDH1A1THRBKMT2A | |
| SCHEMBL20550956 | 0.80 | MAPK1 (0.70) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL20550780 | 0.80 | LMNA (0.48) | LMNASMN1; SMN2ALDH1A1THRBKMT2A | |
| SCHEMBL22286138 | 0.77 | MAPK1 (0.53) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | LMNA 3874/4885SMN1; SMN2 3077/4885ALDH1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.